PubRank

C Sgadari

Author PubWeight™ 26.80‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med 1995 2.99
2 Reactivation and persistence of human herpesvirus-8 infection in B cells and monocytes by Th-1 cytokines increased in Kaposi's sarcoma. Blood 1999 2.10
3 Biology of Kaposi's sarcoma. Eur J Cancer 2001 2.07
4 Contribution of the CXC chemokines IP-10 and Mig to the antitumor effects of IL-12. J Leukoc Biol 1998 1.32
5 The Tat protein of human immunodeficiency virus type-1 promotes vascular cell growth and locomotion by engaging the alpha5beta1 and alphavbeta3 integrins and by mobilizing sequestered basic fibroblast growth factor. Blood 1999 1.25
6 Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. Blood 1999 1.15
7 Inflammatory cytokines synergize with the HIV-1 Tat protein to promote angiogenesis and Kaposi's sarcoma via induction of basic fibroblast growth factor and the alpha v beta 3 integrin. J Immunol 1999 1.10
8 Infection of human endothelial cells with Epstein-Barr virus. J Exp Med 1995 1.10
9 Activation of matrix-metalloproteinase-2 and membrane-type-1-matrix-metalloproteinase in endothelial cells and induction of vascular permeability in vivo by human immunodeficiency virus-1 Tat protein and basic fibroblast growth factor. Mol Biol Cell 2001 1.06
10 Alpha interferon inhibits human herpesvirus 8 (HHV-8) reactivation in primary effusion lymphoma cells and reduces HHV-8 load in cultured peripheral blood mononuclear cells. J Virol 1999 1.04
11 Interleukin-15 promotes angiogenesis in vivo. Biochem Biophys Res Commun 1997 1.02
12 Regression of experimental Burkitt's lymphoma induced by Epstein-Barr virus-immortalized human B cells. Blood 1994 1.02
13 Regression of experimental human leukemias and solid tumors induced by Epstein-Barr virus-immortalized B cells. Leuk Lymphoma 1995 0.89
14 A role for the interferon-inducible protein 10 in inhibition of angiogenesis by interleukin-12. Ann N Y Acad Sci 1996 0.88
15 IFN-gamma induces endothelial cells to proliferate and to invade the extracellular matrix in response to the HIV-1 Tat protein: implications for AIDS-Kaposi's sarcoma pathogenesis. J Immunol 1999 0.87
16 Serum concentrations of fibroblast growth factor 2 are increased in HIV type 1-infected patients and inversely related to survival probability. AIDS Res Hum Retroviruses 2001 0.85
17 Expression of the Epstein-Barr virus protein LMP1 mediates tumor regression in vivo. Blood 1998 0.83
18 Role of the p53 tumor suppressor gene in the tumorigenicity of Burkitt's lymphoma cells. Cancer Res 1997 0.83
19 Epstein-Barr virus as an agent of haematological disease. Baillieres Clin Haematol 1995 0.82
20 High serum interleukin-2 levels in patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma. Nouv Rev Fr Hematol 1989 0.78
21 HIV-Tat down-regulates telomerase activity in the nucleus of human CD4+ T cells. Cell Death Differ 2004 0.78
22 High serum IL-2 levels are predictive of prolonged survival in multiple myeloma. Br J Haematol 1990 0.78
23 Serum interleukin-2 (IL-2), soluble IL-2 receptors and tumor necrosis factor-alfa levels are significantly increased in acute myeloid leukemia patients. Leukemia 1991 0.77
24 Single daily dose ceftriaxone plus amikacin treatment of febrile episodes in neutropenic patients attending day hospital for hematologic malignancies. Oncology 1992 0.77
25 Interleukin-2 continuous infusion and angiogenesis surrogate markers in metastatic renal cell carcinoma. Ann Oncol 2006 0.75
26 Serum interleukin-1 beta levels correlate with neoplastic bulk in hairy cell leukemia. Leukemia 1991 0.75
27 Clearance of human herpesvirus 8 from blood and regression of leukopenia-associated aggressive classic Kaposi's sarcoma during interferon-alpha therapy: a case report. Clin Infect Dis 2001 0.75
28 High serum interleukin-2 levels in acute myeloid leukaemia (AML) are associated with FAB M4 and M5 subtypes. Br J Haematol 1989 0.75
29 Terminal transferase positive acute myeloid leukemia: immunophenotypic characterization and response to induction therapy. Hematol Oncol 1989 0.75
30 High doses of ara-C and m-AMSA in the treatment of refractory acute non lymphocytic leukemia. Haematologica 1990 0.75
31 Acute nonlymphocytic leukemia in the elderly: results of a retrospective study. Haematologica 1989 0.75
32 DHAP treatment: results of 18 patients with refractory or recurrent non Hodgkin's lymphoma. Haematologica 1990 0.75
33 Treatment update for AIDS-related Kaposi's sarcoma. AIDS 1999 0.75
34 Interleukin-18 expression induced by Epstein-Barr virus-infected cells. J Leukoc Biol 2001 0.75